Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Down – What’s Next?

Astellas Pharma Inc. (OTCMKTS:ALPMY) gapped down prior to trading on Monday. The stock had previously closed at $14.20, but opened at $13.48. Astellas Pharma shares last traded at $13.5405, with a volume of 1,081 shares.

Analyst Upgrades and Downgrades

Separately, Zacks Research lowered Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

Astellas Pharma Stock Up 0.3%

The firm’s 50-day moving average price is $14.75 and its 200 day moving average price is $14.46. The firm has a market cap of $26.04 billion, a P/E ratio of 8.59 and a beta of 0.08. The company has a quick ratio of 0.93, a current ratio of 1.20 and a debt-to-equity ratio of 0.16.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Japan-based pharmaceutical company that researches, develops, manufactures and commercializes prescription medicines for patients worldwide. Its portfolio focuses on areas of significant unmet medical need, including oncology, immunology, urology, ophthalmology, neuroscience and medical conditions related to genetic regulation.

The company’s products include XTANDI (enzalutamide) for certain prostate cancers, XOSPATA (gilteritinib) for acute myeloid leukemia, PADCEV (enfortumab vedotin-ejfv) for certain urothelial cancers, and PROGRAF (tacrolimus), an immunosuppressant used primarily to help prevent organ rejection following transplantation.